Ipsen Deal Revamp Increases Independence for Inspiration
A new license, development and commercialization agreement between Inspiration Biopharmaceuticals Inc., of Cambridge, Mass., and Paris-based Ispen SA will restructure the existing partnership between the firms and provide additional funding to Inspiration for development of hemophilia drugs IB1001 and OBI-1.
"Ipsen's been a good partner throughout these negotiations. We both have the same goal in mind, to help patients with hemophilia," Inspiration's chief commercial officer, Dan Regan, told BioWorld Today.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST